Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria.
about
Phenylketonuria: a review of current and future treatmentsDiscovery of Two Cyanobacterial Phenylalanine Ammonia Lyases: Kinetic and Structural Characterization † , ‡Structural and Biochemical Characterization of the Therapeutic Anabaena variabilis Phenylalanine Ammonia LyaseGenetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKUPhenylalanine hydroxylase deficiency.Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria.Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuriaIdentification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuriaBiotechnological production and applications of microbial phenylalanine ammonia lyase: a recent review.Clinical therapeutics for phenylketonuria.Zymophore identification enables the discovery of novel phenylalanine ammonia lyase enzymes.Engineering and kinetic stabilization of the therapeutic enzyme Anabeana variabilis phenylalanine ammonia lyase.Descriptive and hedonic analyses of low-Phe food formulations containing corn (Zea mays) seedling roots: toward development of a dietary supplement for individuals with phenylketonuria.Phenylalanine ammonia-lyase, a key component used for phenylpropanoids production by metabolic engineeringSynthesis of a phenylalanine imprinted polymer for attenuation of phenylalanine absorption via the gut in a murine hyperphenylalaninemia model
P2860
Q26770291-67FE05AF-CB6A-41E5-BA40-74352E6EB1DAQ27641281-825AF2F4-73E6-4F5B-884E-398FE7D3368DQ27650847-C1DCF7CD-5AE1-4A1E-9D6D-2598896B1B93Q33698843-3D68CDB0-0DBC-40AA-AEBD-622E3BB08CF7Q34183829-E98C85CE-66CC-4B8E-834F-F178C7B0D049Q35490408-7CC19E60-51DA-43A2-AA10-FEF8EA410FB4Q36304253-1EF44D70-24C1-4EF2-8D8F-4C99E519CDBFQ36740296-41698616-C580-4726-A5D1-CA8FDE44E587Q37081629-8C1BE803-CB4A-43E1-8EF8-0DDA793E454DQ38107989-877C8909-2DF9-4552-BB99-782B66BF354BQ38383086-D192CB17-9BFB-4523-A9D3-650FE6EFFC47Q42652802-31425874-497E-4A4A-B93F-418EBD4B16B2Q45010181-AA10EB0B-3C62-419D-B764-CF1D8B49C525Q50218729-13FA2723-3F7D-438C-87BA-4C7CEF42FB7DQ56336398-00FDCB05-18DE-4C88-BEC8-860994509DF6Q58828403-A30D0492-BEAF-4860-B915-2DCF5950BA65
P2860
Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Development of pegylated forms ...... of classical phenylketonuria.
@en
Development of pegylated forms ...... of classical phenylketonuria.
@nl
type
label
Development of pegylated forms ...... of classical phenylketonuria.
@en
Development of pegylated forms ...... of classical phenylketonuria.
@nl
prefLabel
Development of pegylated forms ...... of classical phenylketonuria.
@en
Development of pegylated forms ...... of classical phenylketonuria.
@nl
P2093
P1433
P1476
Development of pegylated forms ...... of classical phenylketonuria.
@en
P2093
Alejandra Gámez
Charles O'Neill
Christineh N Sarkissian
Jeffrey F Lemontt
Marianne G Patch
Mary Straub
Paul Fitzpatrick
Steve Striepeke
P304
P356
10.1016/J.YMTHE.2005.02.013
P577
2005-06-01T00:00:00Z